



MEMORANDUM

TO: Marijuana Control Board DATE: September 11, 2019
FROM: Erika McConnell, Director RE: Regulations Project – Testing Oversight

This regulations project contains proposed changes to improve the oversight of testing facilities. At the August 2018 meeting, the board approved a number of legislative requests, including a request for the oversight of testing facility operations to be shifted to the Department of Environmental Conservation. In subsequent months, the interest in that proposal has waned. However, DEC staff and AMCO staff have worked very collaboratively to try to achieve the same goals through changes to the board's regulations at 3 AAC 306.

The attached proposed regulations changes strengthen the role of the board's contractor by:

- requiring the contractor to review testing facility applications and provide a report on the application to the board;
- adopting by reference a testing facility compliance manual (attached) drafted by Steve Crupi of DEC's Environmental Health Lab; and
- requiring any changes to a testing facility's standard operating procedures to be approved by the board's contractor (or the board).

In addition, the requirement for a marijuana testing facility to pay all costs of random validation is removed, but the renewal fee for a testing facility license is proposed to be increased.

These changes support the proposal to have the board contract with DEC to fulfill the role of the board's contractor as referenced in 3 AAC 306 Article 6.

This regulations proposal has not been reviewed by the Testing Working Group, but the group has reviewed the proposed compliance manual.

Based on comments received during a first public comment period, Mr. Crupi revised the draft compliance manual, and the board put the draft regulation back out for public comment. During the second public comment period which closed on September 5, 2019, one comment was received, which are attached.

Options for the board:

- Vote to adopt as written
- Amend; if amendment is significant, put out for public comment
- Send back to staff for revisions
- Close the project without action

3 AAC 306.100(d) is amended to read:

(d) The annual license or endorsement fee, to be paid with each application for a new marijuana establishment facility license or endorsement and each license or endorsement renewal application is

(1) for a new retail marijuana store license, \$5,000, and for a renewed retail marijuana store license, \$7,000;

(2) for a new limited marijuana cultivation facility license, \$1,000, and for a renewed limited marijuana cultivation facility license, \$1,400;

(3) for a new standard marijuana cultivation facility license, \$5,000, and for a renewed standard marijuana cultivation facility license, \$7,000;

(4) for a new marijuana concentrate manufacturing facility license, \$1,000, and for a renewed marijuana concentrate manufacturing facility license, \$2,000;

(5) for a new marijuana product manufacturing facility license, \$5,000, and for a renewed marijuana product manufacturing facility license, \$7,000;

(6) for a new marijuana testing facility license, \$1,000, and for a renewed marijuana testing facility license, ~~\$5,000~~[\$2,000];

(7) for an onsite consumption endorsement to a retail marijuana store license, \$2,000. (Eff. 2/21/2016, Register 217; am 7/19/2017, Register 223; am 8/11/2018, Register 227; am 2/21/2019, Register 229; am ____/____/____, Register ____)

- Authority:** AS 17.38.010 AS 17.38.150 AS 17.38.200
AS 17.38.070 AS 17.38.190 AS 17.38.900
AS 17.38.121

3 AAC 306.620(c) is amended to read:

(c) The board will approve a marijuana testing facility license if, after the board or the board's contractor has examined the qualifications and procedures of the marijuana testing facility license applicant **and documented the conclusions of the examination in a written report**, the board finds them generally in compliance with good laboratory practices **and their application meets the requirements of this section**. Nothing in AS 17.38 or this chapter constitutes a board guarantee that a licensed marijuana testing facility can or will protect the public from all potential hazards of marijuana including microbials, poisons or toxins, residual solvents, pesticides, or other contaminants. (Eff. 2/21/2016, Register 217; am_____/_____/_____, Register____)

Authority:	AS 17.38.010	AS 17.38.150	AS 17.38.200
	AS 17.38.070	AS 17.38.190	AS 17.38.900
	AS 17.38.121		

3 AAC 306.635(a) is amended to read:

(a) An applicant for a marijuana testing facility license and a licensed marijuana testing facility shall

(1) use as guidelines or references for testing methodologies

(A) the American Herbal Pharmacopoeia's Cannabis Inflorescence:

Standards of Identity, Analysis, and Quality Control, Revision 2014, adopted by reference; and

(B) the United Nations Office on Drugs and Crime's Recommended

Methods for the Identification and Analysis of Cannabis and Cannabis Products: Manual

for Use by National Drug Analysis Laboratories, dated 2009 and adopted by reference;
and

(2) notify the board of any alternative scientifically valid testing methodology the marijuana testing facility proposes to use for any laboratory test it conducts; the board may require third-party validation of any monograph, peer-reviewed scientific journal article, or analytical method the marijuana testing facility proposes to follow to ensure the methodology produces comparable and accurate results; **and**

(3) comply with the Marijuana Testing Facility Compliance Document, dated 2019 and adopted by reference; a marijuana testing facility whose license was first issued prior to [effective date] shall comply with this subsection by [effective date + six months].

3 AAC 306.635(c) is amended to read:

(c) The board or the board's contractor may inspect the practices, procedures, and programs adopted, followed, and maintained by the applicant or the licensed marijuana testing facility and may examine all records of the applicant or the licensed marijuana testing facility that are related to the inspection. The board may require an applicant or a licensed marijuana testing facility to have an independent third party inspect and monitor laboratory operations to assess testing competency and the marijuana testing facility's compliance with its quality program. The board may require random validation of a marijuana testing facility's execution of each testing methodology the facility uses. [THE MARIJUANA TESTING FACILITY SHALL PAY ALL COSTS OF VALIDATION.] (Eff. 2/21/2016, Register 217; am __/__/____ Register ____)

Authority: AS 17.38.010 AS 17.38.150 AS 17.38.200

AS 17.38.070

AS 17.38.190

AS 17.38.900

AS 17.38.121

3 AAC 306.640(b) is amended to read:

(b) The scientific director of a marijuana testing facility shall approve, sign, and date each standard operating procedure, and each revision to any standard operating procedure. **Each revision to any standard operating procedure shall be provided to the board within 10 days of approval by the scientific director for review by the board or the board’s contractor. The revised standard operating procedure shall not be implemented until approved by the board or the board’s contractor.** (Eff. 2/21/2016, Register 217; am __/__/____, Register __)

Authority: AS 17.38.010 AS 17.38.150 AS 17.38.200
AS 17.38.070 AS 17.38.190 AS 17.38.900
AS 17.38.121

CANNABIS TESTING LABORATORY COMPLIANCE DOCUMENT

Prepared for:

Alcohol Marijuana Control Office (AMCO)
550 W. 7th Ave., Suite 1600
Anchorage, AK 99501

Revision Date

August 1, 2019 DRAFT

Revision History

This section summarizes revisions made since the last revision of this document.

- Page 4 – Definitions expanded for Duplicate Sample, Internal Standard, Laboratory Control Sample, and Matrix Spikes.
- Page 5 – Definition expanded for Surrogate.
- Page 10 – Minor grammatical changes.
- Page 11 – The sections Selectivity, Peer Review, and Safety Plan and Training moved here from page 13.
- Page 11 – 13 – Quality control samples segregated into two sections, “Preparation Batch QC” and “Analytical Batch QC”.
- Page 14 – Use of negative and positive controls for microbiology QC clarified.
- Page 19 – Clarifications in paragraph 2 where and entire sample cannot be homogenized.

DRAFT

Introduction

Purpose and Scope

The purpose of this document is to establish requirements and guidance for laboratories performing cannabis industry-related testing. Matrices may include, but are not limited to cannabis plant material, concentrates, and consumables.

Exceptions to the requirements are possible through a written appeals process. The appeal shall include:

- an updated SOP
- narrative discussing/supporting the rationale for the appeal
- supporting references or data

The appeal will be reviewed by the Marijuana Control Board (MCB) and/or a designee and subsequently approved, denied, or additional information requested. Exceptions cannot be implemented until written approval from the MCB or designee is issued.

Definitions

Accuracy – a combination of random and systematic error that assesses the difference between a result and a “true” value.

Analyte – a chemical compound or organism of interest.

Analyte group – a collection of chemical compounds or organisms consisting of similar characteristics.

Analytical balance – a type of balance capable of measuring sub-milligram quantities, typically 0.1 mg or better.

Analytical staff – employees with demonstrated competency to routinely prepare samples for testing and/or perform the testing.

Aqueous – a solution in which the base solvent is water.

Audit – a systematic and independent examination.

Batch – a group of samples governed by the same quality control measures and subjected to the same protocols at the same time.

Bias – a tendency towards or away from an expected outcome.

Blank – a material or container absent of a material, analyte, or organism of interest.

Calibration (CB) – the base solvent or reagent used to subject a sample to analysis that is free of the analyte of interest.

Method (MB) – a material free of the analyte of interest.

Temperature (TB) – a media utilized to determine a representative temperature for the entire space of a temperature controlled unit (e.g. sample shipment cooler, refrigerator, oven).

Calibration –

Initial calibration (ICAL) – reference material prepared at incremental concentrations to assess the range within which an instrument can predictively quantitate an analyte of interest.

Continuing calibration verification (CCV) – reference material prepared at a known concentration to determine if instrument performance is at the same level as assessed at the time of the ICAL.

Calibration Range – the concentration range within which an instrument can predictively quantitate an analyte of interest, defined by the lowest and highest possible concentrations. Ideally, it is the range of linear instrument response vs. target analyte concentration.

Chain of custody (COC) – trail of information that documents the sequence of custody, person or storage control, transfer, and final disposition of sample, hardcopy, or electronic evidence.

Comparability – demonstration of a procedure or set of procedures to generate a similar result upon changing a matrix, quality control materials, or quality control operating parameters.

Completeness – a measure of the extent that sample and quality controls meet data quality objectives (e.g.

sensitivity requirements, quality control results within acceptance limits)

Control Material - {compare to reference material}

Correlation coefficient (CC) – a measure of the linear relationship between two or more data points differentiated by each point's concentration.

Corrective action – a change in policy or procedure intended to prevent a nonconformance, anomaly, or unwanted trend from recurring.

Deficiency – lacking something or to describe a situation or material containing less than the desired amount of a particular defining characteristic.

Document – contains or relays information that does not change until there is a change in policy, procedure, or related external reference material or used to record data.

Duplicate Sample – a second portion of a sample, subsampled in the same manner as the original sample and subjected to the same procedures as the original sample and in the same batch as the original sample. One duplicate is required for each preparation for each matrix in a batch. If sufficient sample volume is not available for a duplicate analysis, this requirement may be substituted by generation of an LCSD (LCS duplicate; see definition of LCS below).

Form – A document created by the lab to record visual observations or data. Each form must minimally contain the laboratory name, unique form ID, revision date of the form template, a title indicating the activity being documented, and initials and date of staff recording information.

Internal Standard (IS) – a compound chemically similar to an analyte or analyte of interest, used to independently assess the effectiveness of an analytical procedure on an individual sample, control, or reference material and also serve to quantitate an analyte of interest. The IS is added to the sample after all preparation, cleanup, and dilution steps and immediately prior to introducing the sample, control, or reference material into the instrument. Use of an IS is recommended, but not required.

Laboratory Control Sample (LCS) – a known amount of analyte of interest or chemically similar analyte in addition to the surrogate, added to a blank matrix (i.e. a matrix that does not contain the analyte of interest but is similar in phase (i.e. aqueous, solid, organic (e.g. oil for concentrates or oregano for plants)) to test the effectiveness of a method to test for the analyte in that phase. One LCS is required for each preparation batch of 20 samples or less, regardless of matrix type of samples being tested.

Matrix – the main material; the non-analyte components of a material

Matrix Spike (MS) – a known amount of analyte of interest or chemically similar analyte in addition to the surrogate, added to an aliquot of a sample to test the effectiveness of a method to test for the analyte in that sample's matrix. One MS is required for each preparation batch of plant tissue or edible matrix. The matrix spike assesses a method's extraction efficiency for a given target analyte on a per batch basis as implemented by the lab. The analyte is added after sample reduction, homogenization, and subsampling and just before the start of the sample preparation/extraction phase.

Measurement uncertainty (MU) – an indication of incomplete information of a quantitative value, indicating to what degree the value may be biased on both the low and high end.

Method detection limit (MDL) – the lowest quantity or concentration at which a substance or analyte can be identified with 99% confidence under a given set of conditions.

Method reporting limit (MRL) – the lowest quantity or concentration at which a substance or analyte can be quantitated with 99% confidence under a given set of conditions.

Method validation – demonstrating the effectiveness of implementing a new method, a method new to a lab, or a significant change to an existing method

Method verification – demonstrating the effectiveness of an existing method's ability to manage a new variable, e.g. new matrix, new location of testing, change in reagents, change in prep or testing conditions.

NIST – National Institute of Standards and Technology

Nonconformance – a defect or occurrence that deviates from procedure or falls outside of acceptable limits

PARRCCS – precision, accuracy, representativeness, reproducibility, comparability, completeness, sensitivity

Precision – {Mean % Difference, CV/RPD,} - assess repeatability of a procedure given the same conditions, materials, and steps for each attempt. Common statistical measurements include mean percent difference, relative percent difference (RPD) and coefficient of variation (CV).

Primary source – a vendor that supplies reference material for instrument calibration or as the primary

reference for initially identifying and/or quantifying an analyte of interest.

Quality assurance (QA) – the outline of quality policies and expectations that govern overall how and why a business operates.

Quality control (QC) – daily quality procedures or activities that are implementing a QA program.

Quality manual (QM) – the document that outline quality policies and expectations that govern a business.

Raw data – original numbers collected by an instrument or original observations recorded by a technician.

Record – input or output containing data, observations, or actual operating parameters.

Representativeness – demonstration of thoroughness that a particular procedure or set of procedures is characterizing a sample matrix through identification and quantitation of analytes of interest. Typically an intra-laboratory measure.

Reproducibility – demonstration of a procedure or set of procedures to generate the same result when employed at different labs or if implementation of a procedure change is able to achieve the same result.

Secondary source material – a vendor that supplies reference material from a different lot than the associated primary source that is used to confirm the identity and/or quantitation of an analyte of interest determined by comparison to the primary source.

Sensitivity – the lowest quantity of an analyte of interest that can be observed in a sample, evaluated as part of a method validation for the ability to meet the desired data quality standards.

Subcontract – requesting service from an entity operated as a separate business unit.

Surrogate – a compound chemically similar to an analyte or analyte of interest, used to independently assess the effectiveness of the extraction and analytical procedures on an individual sample, control, or reference material basis. The surrogate is added after sample reduction, homogenization, and subsampling and just before the start of the sample preparation/extraction phase. Surrogate addition is required for plant and edible matrices. The surrogate assesses a method's extraction efficiency on a per sample basis as implemented by the lab for each batch.

Program Administration

Sample Receiving/Login/Storage. A Sample Receiving SOP is required, detailing instructions and requirements for documenting the receipt of samples, such as:

- number of samples received
- the matrix or matrices received
- relinquishing and receiving signatures demonstrating custody transfer
- dates and times of sample collection
- courier delivering the samples (e.g. hand carried, commercial courier)
- verification of sample condition
- sufficient volume received for requested tests
- sample properly preserved and packaged for the tests requested
- documentation of client requested tests
- instructions for receiving samples in METRC
- instructions for reconciling weight discrepancies between METRC and throughout the pre-testing, testing, and post-testing phases of the sample.
- instructions that follow METRC requirements for transferring samples from one lab to another lab.

The SOP must explain how the laboratory tracks and manages samples from receipt, to analysis, to reporting, to storage, to disposal. The detail shall include how samples are uniquely numbered, the internal sample labeling procedures, protocols for reviewing for clerical errors, and sample login data entry errors.

Acceptance/rejection criteria are required in the SOP, including (as applicable):

- identification of who can reject samples
- administrative errors that can result in rejection
- rejection based on weight deficiencies or discrepancies
- rejection based on observations at receiving (e.g. leaking container, obvious contamination)
- procedure for handling rejected samples.

An SOP outlining sample storage procedures is also required, discussing requirements for storing samples upon receipt, during the testing process, and long term storage. Details to include are:

- temperature of storage
- dates of storage, removal of storage, return to storage
- comments (e.g. reason for removing sample)
- the security of the samples and related hardcopy and digital records documenting custody
- initials of the recorder

Subcontracting. Receiving lab must have an Alaska cannabis license and be located within the State of Alaska. If incorporating a subcontract lab result into a report of other results, the subcontract lab must be identified on the report for the result(s) it provided. The report must also include sample custody transfer documentation.

By definition, a subcontract lab is another business unit, whether its own discrete company or a separate business unit (different physical location) of the same company. A customer service center location is not a subcontractor.

Training. The laboratory must document responsibilities, training, and competency for all staff via curriculum vitae (CV), resumes, training records, competency assessment (internal and/or external), and professional certifications. The documentation must identify the analyses and procedures each individual is authorized to independently perform and which require supervision. The criteria for which a person must demonstrate competency for the task or method must be documented.

Record keeping. Visual observations of sample testing that either support the final result or affect the final result must be recorded.

Raw data, including manual integrations (chromatograms representing before and after the manual integration must be available, initialed and dated by the person making the change(s)), including original observations and calculations recorded at the time they were made, having been correctly interpreted and performed.

A data reviewer/auditor must be able to recreate the testing environment with which the results were analyzed/determined. Observations that do not directly factor into the final result, but support test results, confirm integrity of sample, standard, and reagent storage conditions, must also be recorded. Examples include but are not restricted to:

- incubation times and temperatures,
- analysis dates and times
- identification of analysts performing the testing and which steps were completed by each person
- instrument IDs, instrument settings and calibrations (see Laboratory Facilities and Equipment section)
- manufacturer and lot numbers of reagents and materials used
- results of control samples (see Quality Control sections below)
- results of quality control checks performed on media and reagents

Laboratory facilities and equipment – environmental controls, separation of office activities from laboratory

The laboratory must outline protocols in an SOP or throughout SOPs (as applicable) regarding general housekeeping, including glassware cleaning, to avoid the impact of poor housekeeping on the quality of results.

Instrument maintenance logs are required for documenting scheduled (e.g. daily, weekly) and unscheduled maintenance and repair events. The logs are an important tool for troubleshooting and ensuring that all maintenance and repair are in agreement with manufacturer specifications. After adjustments, the instrument must be verified fit for use by analyzing controls, calibration material, or blanks, as appropriate.

Temperature charts and logs are required for documenting adherence to requirements for temperature dependent equipment (e.g. refrigerators, freezers, incubators, water baths) and tests. The frequency of measurements is dependent on the intended use of the unit or the characteristic of the subject method. Units intended for sample preparation and analysis must minimally have start and stop temperatures recorded. Incubation periods that are more than a day require starting temperature readings, a temperature reading each day of the incubation period, and an incubation period ending temperature, including the date and time of each reading, and documenting date and time of the start and stop of the full incubation period. The required temperature range must be stated on each log to assist in identifying outliers. Outliers must be acknowledged on the form, to include corrective action (e.g. temperature adjustment and follow-up reading) or reference to a corrective action document.

Quality Systems

General

This section covers QA, QC, method selection, sample handling, and documentation requirements for the laboratory. The laboratory must discuss these elements in their QM and SOPs (as applicable) and implement them in operations.

Quality manual (QM).

- Defines the laboratory's quality system. Policies and procedures guiding the laboratory are documented or referenced in the QM. Annual review and updates required.
- Identify key staff positions and the corresponding responsibilities.
- Describe how and the frequency in which the possibility of conflicts of interest are assessed and prevention measures in place to identify or avoid conflicts.
- State commitment from management regarding ethics, code of conduct, and commitment to quality.
- Describe calibration requirements for support equipment, covering balances, thermometers (reference and working) (liquid, digital, dataloggers), weights (reference and working), pipettes, and fume hoods. Certificate documentation must be maintained, whether performed in-house or by an outside vendor. In-house service/calibrations required and the associated SOP, documented annual training of technicians, and demonstration of competency for the calibration and service.
- Procedures for calibration, verification, and maintenance of support equipment.
- Detail procedures for control, maintenance, and retention of records and documents.
- Discuss document procedures: error correction, completing forms digitally or on hardcopy, traceability, and record and evidence retention time requirements for hardcopy (sample, testing, and custody evidence related) (5 years required), and digital data acquisition (5 years required).
- Describe calculation and data reduction procedures for results. It is recommended to adopt EPA rules for rounding.
- Describe review and reporting procedures, indicating individual qualifications required to perform data review and reporting.
- Provide procedures for achieving and maintaining traceability of chemical, biological, and metrological standards, reagents, and reference materials used to support or derive any results or measurements.
- Describe sample receiving, control, storage, and disposal handling procedures.
- Describe corrective action procedures – Required:
 - When deviation or nonconformance from policies and procedures are identified.
 - When QC or PT sample results are outside of acceptance limits
 - Identify:
 - The reason for initiating the corrective action.
 - The individual ultimately responsible for action resolution occurring.
 - The date the problem was identified.
 - Source of the problem identified through root cause analysis.
 - Indicate if customer data is impacted.
 - Apply correction.
 - Have a mechanism to verify implementation of the correction and take additional action if initial corrective action implementation fails.

- Document the corrective action process.
- Discuss situations which may occur where data, which do not meet all quality criteria, are accepted and reported to the client and METRC. Authority for making this decision, i.e. professional judgment, must be discussed in the QM, defining what laboratory positions have authorization for making the decision. Situations of professional judgment must be documented in the report's project narrative to include:
 - the nature of the outlier,
 - the QC limit or other criterion not met,
 - the parameter/analyte(s) impacted,
 - the impact on the data,
 - any conversation with the client and resulting outcome(s), and
 - the reason the data are reported, despite the exceedance.
- Demonstration of Capability (staff competence)
- Method selection, validation, and verification procedures
- Measurement traceability
- Measurement uncertainty procedure and frequency of review.

SOPs. Standard operating procedures (SOPs) provide detailed instructions to perform routine operations and practices implemented at the laboratory. These documents represent the procedural flow and give guidance on how to address reasonably anticipated expected and unexpected scenarios.

SOPs must be approved, signed and dated by the Laboratory Director prior to initial use and upon revision. Annual reviews and corresponding updates (if any) are required. SOP documents can be maintained as hardcopy or electronically. If the former, a controlled and documented distribution of documents must be maintained. Only the current versions can be accessible by staff.

Variances to SOPs must be pre-approved by the Laboratory Director or Quality Manager and documented. Each SOP shall have a revision summary that documents the revisions made to generate the current version.

Written procedures are required for calibration, verification, and maintenance of major analytical instruments. Written procedures are required for incorporating and evaluating quality control samples, including, but not limited to instrument tuning and calibration standards, blanks, LCS samples, matrix fortified samples (matrix spikes) and duplicates. Specify QC sample frequency, acceptance criteria, and corrective action guidance for outliers. Either in one document or in several individual documents, discuss protocols for homogenizing samples prior to obtaining a representative subaliquot for testing, and identify instituted controls for not contaminating the source material in the process.

Quality Control Requirements for Chemistry

General. A QC program that includes QC samples, which assess background contamination (background or blank subtraction is not permitted), sensitivity, level of control, level of bias (results may not be adjusted as a result of QC recovery), reproducibility and selectivity. At least annually, the laboratory shall evaluate its QC program, including implementation of QC samples, applicability of acceptance criteria, trends, and document any updates.

- All new and revised methods must be validated prior to use, characterizing the PARRCCS parameters.
- Establish MDL and MRL for testing that results in the reporting of a numerical result.
- Documentation requirements for reagents, controls, and standards –
 - Reagent/Control/Standard containers must be labeled with identity of material.

- Receipt date or preparation date, as applicable.
- Expiration date.
- Receiver's or preparer's initials.
- If received, open date.
- Storage conditions
- Lot number and manufacturer or lab-assigned standard ID number
- Lot numbers or standard ID numbers must be documented for each preparation and analytical batch.

Batching. A preparation or analysis batch consists of at most 20 samples of a similar matrix. Examples:

- Plant samples – Flower, trim, and kief samples can be in the same batch.
- Concentrates – Concentrates can be in one batch, though the laboratory should consider placing samples with an aqueous based solvent (e.g. water) in one batch and samples with an organic based solvent (e.g. oil, butane, propane) in a separate batch.
- Edibles – Segregating edibles into batches is determined by the base constituent of each matrix. For example, separate samples with a flour base from sugar based samples.

For multi-parameter analyses, data acquisition conditions for each parameter must be the same as for all associated quality control samples or measures. The latter includes internal and surrogate standards.

Selectivity. For non-mass spec methods, have a procedure in place to confirm target analyte identity (e.g. dual column, dual detector, dual wavelength, RT windows)

Peer Review. Data review procedures must be sufficient to assess the accuracy, precision, and other performance measures are attained and the tests performed as required to ensure accurate and reliable results are reported. Timing and number of reviewers should be assessed periodically for effectiveness.

Safety Plan and Training.

- Fume hoods are recommended for any work involving toxic chemicals.
- SDS's should be readily available, either hardcopy or electronically.
- Spill kits must be available.
- Signage is recommended for areas where hazardous chemicals are stored and used.
- Fire extinguishers or other fire suppression system is recommended.
- Hand washing stations are required.
- Eye wash stations and emergency showers are recommended.
- Designated space apart from laboratory operations for desk work, eating and drinking is required.

Preparation Batch QC.

- Method blanks (MB) – One MB is required per sample preparation batch of 20 client samples or less. If sample preparation is not a required step, then one MB is required per analytical batch. An MB consists of a matrix similar to the samples and is known to not contain the parameter of interest. For a batch of plant material, a matrix like oregano is an option. An MB is subjected to all of the same steps as a sample. The MB result must be less than the MRL. Samples associated with a failing MB must be re-prepared and reanalyzed with a new set of preparation QC.
- Other Blanks – other blanks may be used by the laboratory depending on the type of method and concerns of the laboratory and/or client. Trip blanks are used to check for interferences encountered during sample collection and handling.

- Surrogates – A compound chemically similar to the test parameter, used to determine method efficiency. The surrogate signal ideally must not interfere with that of the target analytes, or as little as possible. Surrogate addition is required for all organic testing (e.g. potency, terpenes). The surrogate is added to all samples, preparation batch QC samples (including, but not limited to MB, LCS, MS, and Duplicates), and analytical batch QC samples (including, but not limited to calibration standards, calibration check standards, QC or second source standards, MSA analyses, and IB). The surrogate is added to the samples at the beginning step of sample preparation and directly into the matrix. This addition occurs after sample reduction, homogenization, and subsampling processes and is required for plant and edible matrices.

The surrogate is measured in the same way as the target analyte (i.e. same channel or wavelength). The laboratory shall establish performance based QC limits (PBQLs) based on historical data generated at the lab. If sufficient historical data are not available, the laboratory will use 80 – 120% as interim limits until which time sufficient data points are available to generate PBQLs. PBQLs shall represent a 99% confidence interval. Samples and QC samples with surrogate results not meeting the QC limits must be re-prepared and reanalyzed. Preparation batch QC samples with failing surrogate results necessitate the re-preparation of all samples and QC samples.

- LCS – One LCS is required per sample preparation batch of 20 client samples or less. An LCS is subjected to all of the same steps as a sample. The LCS is measured in the same way as the samples (i.e. same channel, wavelength, parent ion, etc.). The laboratory shall establish performance based QC limits (PBQLs) based on historical data generated at the lab. If sufficient historical data are not available, the laboratory will use 80 – 120% as interim limits until which time sufficient data points are available to generate PBQLs. PBQLs shall represent a 99% confidence interval. Samples with target parameter or surrogate results not meeting the QC limits must be re-prepared and reanalyzed. If a recovery failure occurs for a target analyte or surrogate, the entire preparation batch must be re-prepared and reanalyzed. An LCS duplicate (LCS-D) can provide on-going method stability information, and decrease the number of batches needed to accumulate performance-based data.
- MS - One MS is required per sample preparation batch of 20 client samples or less. An MS is subjected to all of the same steps as a sample. The MS is measured in the same way as the samples (i.e. same channel, wavelength, parent ion, etc.). The laboratory shall establish performance based QC limits (PBQLs) based on historical data generated at the lab. If sufficient historical data are not available, the laboratory will use 80 – 120% as interim limits until which time sufficient data points are available to generate PBQLs. PBQLs shall represent a 99% confidence interval. Samples with surrogate results not meeting the QC limits must be re-prepared and reanalyzed. If a recovery failure occurs for a target analyte or surrogate and the recovery is greater than or equal to 50%, data can be accepted if all target analyte and surrogate results in the associated batch LCS are acceptable. If the MS recovery is less than 50%, the parent sample, MS, and associated duplicate must be re-prepared and reanalyzed.
- Duplicate (sample duplicate or matrix spike duplicate) - One duplicate is required per sample preparation batch of 20 client samples or less. Given sufficient sample volume, it is best practice to use the parent sample for the duplicate sample as used for the MS sample. A duplicate sample is subjected to all of the same steps as a sample. The laboratory shall establish performance based QC limits (PBQLs) based on historical data generated at the lab. If sufficient historical data are not available, the laboratory will use an RPD of 20 as an interim limit until which time sufficient data points are available to generate PBQLs. PBQLs shall represent a 99% confidence interval. Samples with surrogate results not meeting the QC limits must be re-prepared and reanalyzed. If an RPD failure occurs for a target analyte and the recovery is less than or equal to 100, data can be accepted if all target analyte and surrogate recovery results in the associated batch LCS are acceptable. If the

duplicate sample RPD recovery is greater than 100, the parent sample, duplicate, and associated MS sample must be re-prepared and reanalyzed.

Analytical Batch QC.

- Instrument blanks (IB) – One IB is required at the start of each analytical batch. The IB consists of the same solvent make-up used to introduce samples onto the instrument. The IB result must be less than the MRL. Samples and preparation batch QC associated with a failing IB must be reanalyzed.
- QC or second source standard – A second source standard must be analyzed immediately after each multi-point initial calibration and before samples and QC samples can be analyzed. Results of this standard must be between 80 – 120% for target analytes and surrogates before sample and QC sample analysis can proceed. If the second source standard is accompanied by a vendor supplied certificate indicating PBQLs specific for the standard, those limits may be used instead.
- Instrument calibration (ICAL) – The ICAL must consist of a minimum of three standards analyzed at varying concentrations with the lowest concentration standard at or greater than the MRL, but greater than zero (0). All standards analyzed to establish the ICAL must be analyzed within a 12-hour period. An acceptable ICAL will have a %RSD greater than or equal to 15%, a linear regression correlation coefficient greater than or equal to 0.995, or a coefficient of determination value greater than or equal to 0.99 for target analytes and surrogates before the second source standard, sample, and QC sample analyses may proceed. Ideally, the calibration is not forced through zero. An IB may be used as an additional calibration point, but it cannot replace one of the three known concentrations.
- Continuing calibration verification (CCV) – A CCV standard, which is prepared from the same stock standard as the ICAL standards, must be analyzed at the start of the run, after every 10 injections, and at the end of the run. If an ICAL starts the analytical run, the CCV must be analyzed after the second source standard and before samples and QC samples are analyzed. The target analytes and surrogates in the CCV must have recoveries between 85 – 115%. Analyses of the sample and QC samples must be bracketed (before and after analysis) by compliant CCVs. Any samples or QC samples associated with a noncompliant CCV must be reanalyzed. Bracketing CCVs must be no longer than 12 hours apart.
- Internal standards (IS) – ISs can be added to samples and preparation and analysis QC samples for quantitative and retention time (RT) shift monitoring purposes. If ISs are used, they must be added to all samples, blanks, and preparation and analysis QC samples. IS addition occurs after all preparation, cleanup, and dilution steps are completed and immediately prior to introduction into the instrument. Use of an IS is recommended, but not required.

The IS area and RT data are compared to the area(s) and RT(s) of the mid-level standard in the ICAL. The quality control limits for the area are from 50% to 200% percent of the IS area in the mid-level ICAL standard. The quality control limits for the RT are ± 0.50 minutes of the IS RT in the mid-level ICAL standard. If the IS area or RT does not fall within the QC limits, the sample or QC sample must be reanalyzed.

Quality Control Requirements for Microbiology.

Documentation requirements for reagents, controls, and standards –

- Reagent/Control/Standard containers must be labeled with identity of material.
- Receipt date or preparation date, as applicable.

- Expiration date.
 - Receiver's and/or preparer's initials.
 - Open date.
 - Storage conditions
 - Lot number or lab-assigned standard ID number
 - Lot numbers or standard ID numbers must be documented for each preparation and analytical batch.
- Negative control –Negative controls will differ depending on the technology used. For media methods, the negative control contains another organism to demonstrate method selectivity. The organism may be similar in nature to the target organism and does not produce the same reaction as the target organism. For media based methods, one negative control must be analyzed on each lot of media before use. If a negative control fails and samples were analyzed concurrently, samples with a negative result may be reported with comment. All other samples must be invalidated. For qPCR, a negative control is a blank sample made with a reagent that does not contain an organism (e.g. sterile water). For qPCR, a negative control is required for every batch, or more often if required by the manufacturer's validated method (reference method). If a negative control fails, associated samples with a negative result may be reported with comment. All other samples must be invalidated.
 - Positive control – Positive controls will differ depending on the technology used. For media methods, the positive control contains the target analyte/strain of interest. For media based methods, one positive control must be analyzed on each lot of media before use. If a positive control fails and samples were analyzed concurrently, presence/absence samples with a positive result may be reported with comment. All other samples must be invalidated. For qPCR, a positive control contains either the target analyte/strain of interest or a commercial positive control, based on manufacturer's instructions. For qPCR, a positive control is required for each analyte/strain of interest for every batch, or more often if required by the reference method. If a positive control fails, associated presence/absence samples with a positive result may be reported with comment. All other samples must be invalidated.
 - Duplicate sample - One duplicate is required per sample batch of five (5) client samples or less. A duplicate sample is subjected to all of the same steps as the original sample. For qualitative analyses, if the duplicate sample does not equal the sample result, the sample and its duplicate must be reanalyzed. Consideration should also be given to possibility of re-preparing and reanalyzing all associated samples. For quantitative analyses, if the RPD of the sample and duplicate is greater than 100, the parent sample and duplicate sample must be reanalyzed. Consideration should also be given to possibility of re-preparing and reanalyzing all associated samples. When data are accepted, the result for the sample portion designated as the "original sample" is reported.
 - Temperature monitoring (see "Laboratory facilities and equipment")
 - Sample preparation documentation is required for pre-enrichment and sample preparation steps and shall include the unique ID of the negative and positive controls, the client samples associated with the controls, the weight of the subsample used, the unique ID of all media and reagents used in pre-enrichment and to prepare the samples, dates/times and temperature samples are placed into and remove from the incubator, the preparer's initials, and the date and time of preparation.
 - Sample analysis documentation is required. Time and date samples are placed in the incubator, removed from incubator, and analyzed or examined must be recorded, along with observations or instrument raw data.
 - Any verification steps required by the method must also meet the same documentation requirements

as preparation and analysis.

- Documentation of macroscopic and microscopic examinations shall include pictures and written observations.

DRAFT

Reporting

The laboratory report is required to contain the following elements.

- Testing laboratory’s name and physical address. If a subcontract laboratory is used for part or all of the testing, the report must identify the name of the subcontract laboratory and identify the specific testing it performed.
- The report date.
- A unique sample number or alpha-numeric number assigned by the laboratory’s receiving and accessioning processes.
- The name of the person submitting the sample for testing and the identifier assigned by the submitter for each sample.
- The date and time the laboratory received the sample.
- Sample matrix.
- The chain of custody record documenting the transfer of the sample from the submitter to the laboratory. If the laboratory submits a sample to a subcontract laboratory, documentation of that custody transfer must also be included in the report.
- A name for each test method and identity of each individual parameter determined by the method.
- The published method or laboratory SOP unique ID for each test method.
- The numerical or text result for each method or individual parameters of a method. If the parameter is not detected, the laboratory can provide the result as “Not Detected”, “ND”, “Not found”, etc.
- The units for each result, as applicable. If the parameter is not detected, the units are still required for the report.
- The MRL for each numerical result, as applicable. If the parameter is not detected, the MRL is still required for the report.
- A report project narrative discussing anomalies or quality control outliers and related corrective action steps encountered during sample receiving, sample preparation, or analytical testing.
- Report results to the MRL, as applicable, unless otherwise specified on a per client or per project basis.
- Amended reports must indicate in the report project narrative what changed from the original report, the reason for the change, and the date of the revised report.
- Chemistry results for plant material must be reported on a dry weight basis (DWB). The percent (%) moisture of the plant sample ‘as received’ must be reported separately. The % moisture value is used to calculate the dry weight chemistry result. Chemistry results for all other sample matrices are reported on an ‘as received’ basis.

$$\text{Result (DWB)} = \text{wet wt. sample result} \times \frac{100}{100 - \% \text{ moisture}}$$

- Each required test, whether failing or passing, must be reported in METRC within 24 hours (i.e. one (1) calendar day) of the test completing as per 3AAC306.670. “Test completing” is defined by this document as the sample and related preparation batch and analytical batch QC have been successfully analyzed.

Proficiency Testing

To obtain and maintain a license to perform testing, the laboratory must participate in Proficiency Testing (PT) for each test. This testing ensures accurate results are being produced by licensed laboratories, regardless of methodology. For multi-parameter tests (e.g. potency and terpenes testing), the laboratory must successfully identify and quantitate 80% of the target analytes. Any false positive or false negative results are considered unsatisfactory.

Required analyses – applies to regulated constituents (*Aspergillus niger, flavus, fumigatus, E.coli, Salmonella*, THC, THCA, CBD, CBDA, CBN for each matrix being tested. Sample matrices are cannabis plant material, any edible matrix, or a concentrate. PTs are required for a new analyst, a method validation, and ongoing on an annual basis per lab (vs. per analyst).

Treatment of PT samples – PT samples are treated the same as commercial samples, undergoing the same size reduction, subsampling, pre-treatment, extraction, number of analyses, and analysis procedures. If any special handling is necessary (e.g. sample prep, unit conversion), this treatment is documented with the statement. PT samples may not be reanalyzed to confirm results, may not be analyzed in duplicate, or analyzed with additional QC beyond what is performed for client samples.

Laboratories may report multiple results for a given sample that represent multiple prep and/or analytical protocols/combinations, multiple matrices, or multiple analytical staff. Laboratories may not send a PT sample to another lab and report that lab's result(s). Conversely, a laboratory may not knowingly analyze a PT sample received from another laboratory. Laboratories may not compare results with another laboratory.

The Laboratory Director must sign an attestation statement when submitting results that indicates the PT samples were integrated into the routine sample workflow and did not receive special treatment.

Reporting - PT reports are submitted to the entity producing and issuing the samples for scoring. Score reports are sent to the laboratory and AMCO simultaneously. The scored results may be used in part or in whole for decisions regarding licensing/certification status. Reports of PT results may be amended when errors attributed to the PT sample provider are identified or when a clerical error unique to the reporting of PT samples is discovered. The reason for an amended report must be discussed in the PT report project narrative and is subject to rejection or request for additional information issued by the PT provider or AMCO.

Acceptance limits and grading – established by the PT provider and determined by provider's in-house testing, factoring in participating lab performance. Acceptance limits are associated with all quality control testing processes and analytes.

Corrective action – see corrective action in QM section.

Audits

Internal. One internal audit for each sample preparation and test method the laboratory performs must be conducted within six months from the date of implementation. A report must be generated for each internal audit, containing:

- Audit date(s)
- Auditor name
- Date of the report
- Title of the report indicating the method(s) audited
- Name(s) of staff interviewed for the audit
- Questions/topics explored during the audit
- Findings
- Due date for corrective action response

Internal audit reports and the associated corrective action response must be minimally available for inspection within five years of the end of the audit.

Internal audits may be horizontal or vertical in nature. A horizontal audit reviews one particular aspect that is implemented across a laboratory, e.g. document control. A vertical audit reviews one aspect of an operation that is not performed throughout an organization, e.g. extraction for potency testing. These audits are intended, in part, to assess adherence to SOPs and good laboratory practice and to perform a gap analysis of a procedure or quality system(s).

Auditor qualifications for internal audits

The concept of someone being trained or qualified as an auditor is defined by a person's skill set and experience. The following aspects are traits and skills to evaluate when identifying a person to be an internal auditor. All of the items below are not required to have a 'yes' answer.

- Overall technical knowledge and experience relative to the audit subject.
- Objective thinking ability.
- Capability to investigate independent of a checklist and has the initiative to pursue unplanned routes of inquiry.
- Professionalism demonstrated with sound judgment and strength in interpersonal skills.
- Fair and respectful of confidentiality when needed.
- Understanding of the lab's quality policies and procedures.
- Ability to stay focused on an audit scope.
- Ability to write a detailed and coherent narrative.

External. External audits may be requested and/or conducted by AMCO or other entity that is an unrelated business concern to the laboratory. The laboratory must allow access to the laboratory and all documentation for purposes of the onsite audit, in order to maintain laboratory certification with AMCO. The resulting audit reports and the corrective action response(s) must be submitted to the auditor and AMCO within one week of completion of the corrective action plan, even if not all of the corrective actions have been implemented or verified to be effective. All corrective actions must be approved by the auditing entity before the audit is considered to be closed.

Corrective action – see corrective action in QM section.

Homogenization and Subsampling Considerations

Homogenization can be thought of as two parts: breaking the sample down into smaller pieces, and mixing those pieces uniformly. While breaking down a sample into smaller pieces may need only occur initially, mixing should take place each time a subsample is taken. All samples are expected to exhibit some degree of non-uniform distribution of target analytes. Therefore, the entire sample should, ideally, be homogenized before taking subsamples or aliquots for testing.

If not practical to homogenize the entire sample, multiple portions must be taken from all parts of the sample, combined, and homogenized before a single subsample is taken for testing. Considerations must be taken to prevent contamination or cross contamination between samples. Using clean (sterile if microbiology testing) scissors/scalpel and tweezers to randomly and representatively collect multiple portions. Visually assess the sample for varying features, taking portions from each feature. If the sample is in a container that makes difficult accessing all areas of the sample, considering emptying the sample out onto a clean (sterile if microbiology testing) surface.

The QA Manual or SOP(s) must describe, in detail, homogenization and subsampling procedures, including:

- How are subsamples taken?
- How are sample materials homogenized?
- What are the required sample sizes for different types of samples and tests?
- Sample homogenization and subsampling for each of the following types of samples:
 - Flower and other plant parts may be homogenized in a mill, blender, food processor, laboratory homogenizer or other mechanical method.
 - Concentrates: Liquid concentrates may be homogenized by agitation (vortexing, blending, or shaking) before subsamples are aliquoted. Foam generated during agitation can result in a non-homogeneous distribution of target parameters. Use mechanical means (e.g. sterile wood applicator), freezing, or chemical means (e.g. mixing in salt) to force the foam back into solution. If multiple subsamples are taken, agitation should take place frequently during subsampling (no more than about two minutes should elapse between agitation and aliquoting). Thicker (oil like) concentrates may be mixed using sterile spoons or other utensils (clean utensils free of the analytes of interest may be used if not sampling for microorganisms.)
 - Edibles: Consideration for each of the following types of edibles must also be described in detail:
 - Flour Based: may be homogenized using a mill, blender, food processor, laboratory homogenizer, or other chemical method.
 - Sugar Based: may require different techniques depending on the matrix. Hard candies or chocolates may be pulverized in a mill or food processor (avoid elevated temperatures), while gummies and other soft/chewy candies may be cut into small pieces using sterile utensils. (Note: FDA recommends mixing hard candies/caramels with equal masses of water and heat to boiling, except if testing for microbial or volatile constituents.)
 - Drinks: may be homogenized by agitation (vortexing, blending, or shaking) before subsamples are aliquoted. If multiple subsamples are taken, agitation should take place frequently during subsampling (no more than 2 minutes

- should elapse between agitation and aliquoting).
- Crystalline: may be broken down into finer particles and homogenized by blenders, food processors, mills, or a laboratory homogenizer before taking subsamples.

DRAFT

From: [kara_jurczak](#)
To: [CED AMCO REGS \(CED sponsored\)](#)
Subject: Proposed Lab Testing Document: Comments
Date: Thursday, September 05, 2019 4:29:30 PM

To AMCO,

Peak analytical LLC has the following comments regarding the proposed laboratory compliance document.

Firstly, we are wondering what problems/deficiencies this document is addressing? We have not heard of any documented illnesses due to potency, microbial, terpene or residual solvent contamination of Marijuana flower or product in the state of Alaska. We agree that regulations are necessary when a new societal problem needs to be solved. This document appears to be adding regulations, without a clear scientific reference or reasoning.

We can only surmise that the root of the issue, is varying results among the existing labs. Any scientist knows, there is significant variability between random samples, as well as various natural variables (location, season, equipment, staff, etc.) than can affect the results of one strain, not to mention the variability between labs (solvents used, machine manufacturer, staff technique, etc).

With that said, these additional (and costly) requirements will not reduce inter-lab variability, and will only serve to stifle the freedom and resources we have to dedicate to scientific development in this constantly expanding and changing industry.

This document requires a MINIMUM of 7 quality control samples per batch of client samples.

I have the following comments regarding the proposed MTF Compliance Document (CD). Generally I think it is a good document; however, the quality control (QC) requirements for chemistry are excessive to say the least. According to the proposed CD I have to run seven quality control samples with every client batch. I often run batches of three or less (our top client brings in ONE sample a day) client samples so this document would require double the amount of QC samples than client samples on most days for me. This would double the preparation time and consumables costs for every client batch. The amount of QC and overall lab documentation required in this CD requires a full time employee all on it's own. The northern labs might have the client volume and staff to survive such a regulation but in Ketchikan this regulation would be a fatal blow. Let's apply this proposed regulation to terpene and residual solvent analysis via gas chromatography. My methods for these two tests run about 45 minutes per vial and the instrument takes an hour to warm up. That would mean six hours and fifteen minutes of my day would be consumed just to get through the QC samples; that is excessive and leaves almost no time to run client samples. Currently I only have the client volume to staff one other employee; this regulation would double the work and expenses without adding revenue to pay for more employees to perform all these daily QC samples and documentation. Small, low volume labs like myself will not be able to perform this level of daily QC from a monetary standpoint. I recommend the committee reconsider

what is a reasonable, realistic and necessary amount of QC to perform with EVERY client batch. Furthermore, running seven different QC samples with every batch far exceeds the analytical laboratory standards of practice. I recommend the committee reconsider what is a reasonable, realistic and necessary amount of QC to perform with every client sample batch. In the future, we would more heartily support additions, if any proposed changes were accompanied by peer-reviewed scientific studies that supported their validity and necessity. My lab performs all the proposed QC samples at various times but not with every client batch or every other client batch (except the CCV and IB which are done with each batch). Typically these additional QC samples are performed periodically with audits, management reviews, quality system reviews, method performance evaluations, etc. Simply put, the proposed regulation squeezes the profitability out of the cannabis testing business and may or may not accomplish anything as a result. Furthermore, this regulation will be very costly to the state to administer and oversee. It's a lose, lose situation.

Every cannabis testing lab in the state is striving to achieve the most scientifically valid, highest quality, and defensible methodology and results possible, as a function of simply staying in business. If a person becomes ill from contaminated product, AMCO fines, client confidence, and insurance hikes are already the greatest deterrents to a lab failing to provide defensible and the most accurate results

Regarding the quality control samples and their required frequency:

- Duplicate: Frequency varies throughout document without explanation as to why. We do agree duplicate samples increase statistical soundness of a result.
- Lab Control Sample: Spiking any matrix is difficult and highly variable between analysts, furthermore I do not see how this evaluates the effectiveness to test an analyte in a particular phase
- Matrix Spike: See above, in regards to difficulty and variability with spiking samples. How does this evaluate extraction efficiency? Matrix spikes are typically used for method development and validation, not day to day QC.
- Surrogate: What would a surrogate for cannabinoids be? Do we need a surrogate for every single cannabinoid and every solvent? How does this evaluate extraction efficiency? Each lab will be using different surrogates, by different manufacturer's?
- Method Blank: We cannot figure out what testing oregano or olive oil accomplishes, please explain.
- CCV: Industry standards use one CCV per batch. What will using more CCV's accomplish?
- Secondary Source Standard: A batch of CRMs, to test potency, terpenes and RSA costs \$1000 and lasts 4 months. This regulation requires doubling this expense. What does it accomplish?

Thank you for your consideration.

Julie Martellini, PhD
Kara Jurczak, PE
Peak Analytical LLC